Literature DB >> 15967079

Ocular cicatricial pemphigoid: manifestations and management.

John H Chang1, Peter J McCluskey.   

Abstract

Ocular cicatricial pemphigoid (OCP) is a chronic, progressive cicatrizing inflammatory disease of presumed autoimmune etiology affecting the mucous membranes and skin. It has sight-threatening ocular manifestations and potentially life-threatening extraocular manifestations. The ocular signs include: chronic cicatricial conjunctivitis, progressive conjunctival fibrosis, and corneal epitheliopathy. Systemic immunomodulatory therapy is the treatment of choice for controlling disease activity and limiting progression, given the systemic nature of the disease and the poor efficacy of current local or topical therapies. Systemic cyclophosphamide with short-term adjunctive high-dose prednisolone is the preferred treatment for severe and/or rapidly progressing OCP. Oral low-dose weekly methotrexate is a useful first-line treatment for mild-to-moderate OCP. The management of OCP requires a multidisciplinary approach to optimize the care of these patients.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15967079     DOI: 10.1007/s11882-005-0078-9

Source DB:  PubMed          Journal:  Curr Allergy Asthma Rep        ISSN: 1529-7322            Impact factor:   4.919


  26 in total

1.  Improved detection of disease progression in ocular cicatricial pemphigoid.

Authors:  J Tauber; N Jabbur; C S Foster
Journal:  Cornea       Date:  1992-09       Impact factor: 2.651

2.  [On the so-called ocular pemphigus (pemphigus ocularis, pemphigus conjunctivae)].

Authors:  H Bettelheim; D Kraft; G Zehetbauer
Journal:  Klin Monbl Augenheilkd       Date:  1972-01       Impact factor: 0.700

3.  Benign mucous membrane pemphigoid.

Authors:  K M Hardy; H O Perry; G C Pingree; T J Kirby
Journal:  Arch Dermatol       Date:  1971-11

4.  Intravenous immunoglobulin therapy for ocular cicatricial pemphigoid: a preliminary study.

Authors:  C S Foster; A R Ahmed
Journal:  Ophthalmology       Date:  1999-11       Impact factor: 12.079

Review 5.  The immunological features and pathophysiology of ocular cicatricial pemphigoid.

Authors:  M J Elder; S Lightman
Journal:  Eye (Lond)       Date:  1994       Impact factor: 3.775

6.  Treatment of ocular cicatricial pemphigoid with sulfasalazine.

Authors:  S Doan; J F Lerouic; H Robin; C Prost; M Savoldelli; T Hoang-Xuan
Journal:  Ophthalmology       Date:  2001-09       Impact factor: 12.079

7.  Methotrexate therapy for ocular cicatricial pemphigoid.

Authors:  Peter McCluskey; John H Chang; Ravi Singh; Denis Wakefield
Journal:  Ophthalmology       Date:  2004-04       Impact factor: 12.079

8.  Low-dose methotrexate therapy for ocular inflammatory disease.

Authors:  S S Shah; C Y Lowder; M A Schmitt; W S Wilke; G S Kosmorsky; D M Meisler
Journal:  Ophthalmology       Date:  1992-09       Impact factor: 12.079

9.  Intravenous immunoglobulin therapy in patients with ocular-cicatricial pemphigoid: a long-term follow-up.

Authors:  Naveed Sami; Erik Letko; Sofia Androudi; Yassine Daoud; C Stephen Foster; A Razzaque Ahmed
Journal:  Ophthalmology       Date:  2004-07       Impact factor: 12.079

10.  Mucous membrane pemphigoid and pseudopemphigoid.

Authors:  Jennifer E Thorne; Grant J Anhalt; Douglas A Jabs
Journal:  Ophthalmology       Date:  2004-01       Impact factor: 12.079

View more
  7 in total

1.  Clinical features and in vivo confocal microscopy assessment in 12 patients with ocular cicatricial pemphigoid.

Authors:  Qin Long; Ya-Gang Zuo; Xue Yang; Ting-Ting Gao; Jie Liu; Ying Li
Journal:  Int J Ophthalmol       Date:  2016-05-18       Impact factor: 1.779

2.  The evil curse of ocular pemphigoid.

Authors:  P Hossain
Journal:  Eye (Lond)       Date:  2011-09       Impact factor: 3.775

Review 3.  The 2016 Bowman Lecture Conjunctival curses: scarring conjunctivitis 30 years on.

Authors:  J K Dart
Journal:  Eye (Lond)       Date:  2017-01-20       Impact factor: 3.775

4.  Aldehyde dehydrogenase inhibition blocks mucosal fibrosis in human and mouse ocular scarring.

Authors:  Sarah D Ahadome; David J Abraham; Suryanarayana Rayapureddi; Valerie P Saw; Daniel R Saban; Virginia L Calder; Jill T Norman; Markella Ponticos; Julie T Daniels; John K Dart
Journal:  JCI Insight       Date:  2016-08-04

5.  Long-term rebamipide and diquafosol in two cases of immune-mediated dry eye.

Authors:  Mio Yamane; Yoko Ogawa; Masaki Fukui; Mizuka Kamoi; Yumiko Saijo-Ban; Saori Yaguchi; Shin Mukai; Tetsuya Kawakita; Shigeto Simmura; Kazuo Tsubota
Journal:  Optom Vis Sci       Date:  2015-04       Impact factor: 1.973

6.  Defining the limits of normal conjunctival fornix anatomy in a healthy South Asian population.

Authors:  Imran J Khan; Abdul-Jabbar Ghauri; James Hodson; Matthew R Edmunds; Paul Cottrell; Simon Evans; Geraint P Williams; Saaeha Rauz
Journal:  Ophthalmology       Date:  2013-12-04       Impact factor: 12.079

Review 7.  Role of immune cells in the ocular manifestations of pemphigoid diseases.

Authors:  Tanima Bose
Journal:  Ther Adv Ophthalmol       Date:  2019-08-08
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.